Which medications in the drug class Platelet Aggregation Inhibitors are used in the treatment of Coronary Artery Atherosclerosis?

Updated: Apr 09, 2021
  • Author: Sandy N Shah, DO, MBA, FACC, FACP, FACOI; Chief Editor: Yasmine S Ali, MD, MSCI, FACC, FACP  more...
  • Print
Answer

Platelet Aggregation Inhibitors

Platelet aggregate inhibitors may have a positive influence on several hemorrhagic parameters and may exert protection against atherosclerosis through inhibition of platelet function and through changes in the hemorrhagic profile.

Platelet aggregate inhibitors include the following:

- Clopidogrel (Plavix)

- Abciximab (ReoPro)

- Aspirin (Anacin, Ascriptin, Bayer Aspirin, Bayer Buffered Aspirin)

Clopidogrel selectively inhibits ADP binding to platelet receptors and subsequent ADP-mediated activation of the glycoprotein IIb/IIIa complex, thereby inhibiting platelet aggregation.

Abciximab is a chimeric human-murine monoclonal antibody approved for use in elective/urgent/emergent PCI. It binds to receptors with high affinity and reduces platelet aggregation by 80% for up to 48 hours following infusion. Abciximab prevents acute cardiac ischemic complications in patients with unstable angina that is unresponsive to conventional therapy.

Aspirin inhibits prostaglandin synthesis, preventing the formation of platelet-aggregating thromboxane A2. Aspirin may be used in low doses to inhibit platelet aggregation and to improve complications of venous stases and thrombosis.

Clopidogrel

Selectively inhibits ADP binding to platelet receptor and subsequent ADP-mediated activation of glycoprotein IIb/IIIa complex, thereby inhibiting platelet aggregation.

Abciximab (ReoPro)

Chimeric human-murine monoclonal antibody approved for use in elective/urgent/emergent percutaneous coronary intervention. Binds to receptor with high affinity and reduces platelet aggregation by 80% for up to 48 h following infusion. Prevents acute cardiac ischemic complications in patients with unstable angina unresponsive to conventional therapy.

Aspirin (Anacin, Ascriptin, Bayer Aspirin, Bayer Buffered Aspirin)

Inhibits prostaglandin synthesis, preventing formation of platelet-aggregating thromboxane A2. May be used in low dose to inhibit platelet aggregation and improve complications of venous stases and thrombosis.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!